Zydus Cadila Announced That It Has Completed Enrollment In Evidences Ii, Evidences Iii And Evidences V Phase 3 Clinical Trials Of Saroglitazar Mg For Treating Non-Alcoholic Steatohepatitis (Nash). Patients With Nash Have Been Enrolled In These Trials Across Clinical Sites In India And Mexico. Pankaj R. Patel, Chairman, Zydus Group Said,
